These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 34551297)

  • 1. DOT1L O-GlcNAcylation promotes its protein stability and MLL-fusion leukemia cell proliferation.
    Song T; Zou Q; Yan Y; Lv S; Li N; Zhao X; Ma X; Liu H; Tang B; Sun L
    Cell Rep; 2021 Sep; 36(12):109739. PubMed ID: 34551297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia.
    Wang E; Kawaoka S; Yu M; Shi J; Ni T; Yang W; Zhu J; Roeder RG; Vakoc CR
    Proc Natl Acad Sci U S A; 2013 Mar; 110(10):3901-6. PubMed ID: 23412334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.
    Wang WT; Chen TQ; Zeng ZC; Pan Q; Huang W; Han C; Fang K; Sun LY; Yang QQ; Wang D; Luo XQ; Sun YM; Chen YQ
    J Hematol Oncol; 2020 Jun; 13(1):78. PubMed ID: 32552847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia.
    Richter WF; Shah RN; Ruthenburg AJ
    Elife; 2021 Jul; 10():. PubMed ID: 34263728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.
    Nguyen AT; Taranova O; He J; Zhang Y
    Blood; 2011 Jun; 117(25):6912-22. PubMed ID: 21521783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DOT1L activity in leukemia cells requires interaction with ubiquitylated H2B that promotes productive nucleosome binding.
    Spangler CJ; Yadav SP; Li D; Geil CN; Smith CB; Wang GG; Lee TH; McGinty RK
    Cell Rep; 2022 Feb; 38(7):110369. PubMed ID: 35172132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.
    Bernt KM; Zhu N; Sinha AU; Vempati S; Faber J; Krivtsov AV; Feng Z; Punt N; Daigle A; Bullinger L; Pollock RM; Richon VM; Kung AL; Armstrong SA
    Cancer Cell; 2011 Jul; 20(1):66-78. PubMed ID: 21741597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RE-IIBP Methylates H3K79 and Induces MEIS1-mediated Apoptosis via H2BK120 Ubiquitination by RNF20.
    Woo Park J; Kim KB; Kim JY; Chae YC; Jeong OS; Seo SB
    Sci Rep; 2015 Jul; 5():12485. PubMed ID: 26206755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.
    Liu W; Deng L; Song Y; Redell M
    PLoS One; 2014; 9(5):e98270. PubMed ID: 24858818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
    Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
    Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone methyltransferase Dot1L recruits O-GlcNAc transferase to target chromatin sites to regulate histone O-GlcNAcylation.
    Xu B; Zhang C; Jiang A; Zhang X; Liang F; Wang X; Li D; Liu C; Liu X; Xia J; Li Y; Wang Y; Yang Z; Chen J; Zhou Y; Chen L; Sun H
    J Biol Chem; 2022 Jul; 298(7):102115. PubMed ID: 35690146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.
    Chen CW; Armstrong SA
    Exp Hematol; 2015 Aug; 43(8):673-84. PubMed ID: 26118503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the Lysosome-Associated Membrane Protein LAMP5 by DOT1L Serves as a Bodyguard for MLL Fusion Oncoproteins to Evade Degradation in Leukemia.
    Wang WT; Han C; Sun YM; Chen ZH; Fang K; Huang W; Sun LY; Zeng ZC; Luo XQ; Chen YQ
    Clin Cancer Res; 2019 May; 25(9):2795-2808. PubMed ID: 30651276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
    Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
    Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.
    Deshpande AJ; Chen L; Fazio M; Sinha AU; Bernt KM; Banka D; Dias S; Chang J; Olhava EJ; Daigle SR; Richon VM; Pollock RM; Armstrong SA
    Blood; 2013 Mar; 121(13):2533-41. PubMed ID: 23361907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity.
    Skucha A; Ebner J; Schmöllerl J; Roth M; Eder T; César-Razquin A; Stukalov A; Vittori S; Muhar M; Lu B; Aichinger M; Jude J; Müller AC; Győrffy B; Vakoc CR; Valent P; Bennett KL; Zuber J; Superti-Furga G; Grebien F
    Nat Commun; 2018 May; 9(1):1983. PubMed ID: 29777171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tip60 activates Hoxa9 and Meis1 expression through acetylation of H2A.Z, promoting MLL-AF10 and MLL-ENL acute myeloid leukemia.
    Yamagata K; Shino M; Aikawa Y; Fujita S; Kitabayashi I
    Leukemia; 2021 Oct; 35(10):2840-2853. PubMed ID: 33967269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
    Yuan Y; Du L; Tan R; Yu Y; Jiang J; Yao A; Luo J; Tang R; Xiao Y; Sun H
    J Med Chem; 2022 Jun; 65(11):7770-7785. PubMed ID: 35612819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential.
    Kuntimaddi A; Achille NJ; Thorpe J; Lokken AA; Singh R; Hemenway CS; Adli M; Zeleznik-Le NJ; Bushweller JH
    Cell Rep; 2015 May; 11(5):808-20. PubMed ID: 25921540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias.
    Yi Y; Ge S
    J Hematol Oncol; 2022 Mar; 15(1):35. PubMed ID: 35331314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.